(7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acids as S1P1 Functional Antagonists.

S1P1 is a validated target for treatment of autoimmune disease, and functional antagonists with superior safety and pharmacokinetic properties are being sought as second generation therapeutics. We describe the discovery and optimization of (7-benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acids as potent, centrally available, direct acting S1P1 functional antagonists, with favorable pharmacokinetic and safety properties.

[1]  M. Bolli,et al.  Sphingosine 1-Phosphate (S1P) Receptor Agonists Mediate Pro-fibrotic Responses in Normal Human Lung Fibroblasts via S1P2 and S1P3 Receptors and Smad-independent Signaling , 2013, The Journal of Biological Chemistry.

[2]  M. Imai,et al.  Efficacy and immunomodulatory actions of ONO‐4641, a novel selective agonist for sphingosine 1‐phosphate receptors 1 and 5, in preclinical models of multiple sclerosis , 2013, Clinical and experimental immunology.

[3]  D. Sengupta,et al.  Complementary asymmetric routes to (R)-2-(7-hydroxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetate. , 2012, Organic letters.

[4]  N. Gray,et al.  The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate , 2012, British journal of pharmacology.

[5]  D. Sengupta,et al.  Fused tricyclic indoles as S1P₁ agonists with robust efficacy in animal models of autoimmune disease. , 2012, Bioorganic & medicinal chemistry letters.

[6]  D. Geerts,et al.  Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier , 2012, Journal of Neuroinflammation.

[7]  A. Goodman.  News from the AAN Annual Meeting: Novel Agent Reduces MS. Lesions in Early Trial , 2012 .

[8]  D. Hafler,et al.  Fingolimod for multiple sclerosis. , 2012, The New England journal of medicine.

[9]  M. Lipp,et al.  Sphingosine‐1‐phospate receptor 4 (S1P4) deficiency profoundly affects dendritic cell function and TH17‐cell differentiation in a murine model , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  C. Constantinescu,et al.  Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS) , 2011, British journal of pharmacology.

[11]  S. Dowell,et al.  Discovery of a brain-penetrant S1P₃-sparing direct agonist of the S1P₁ and S1P₅ receptors efficacious at low oral dose. , 2011, Journal of medicinal chemistry.

[12]  J. Chun,et al.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). , 2011, Discovery medicine.

[13]  F. Jadidi-Niaragh,et al.  Th17 Cell, the New Player of Neuroinflammatory Process in Multiple Sclerosis , 2011, Scandinavian journal of immunology.

[14]  D. Herr,et al.  FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation , 2010, Proceedings of the National Academy of Sciences.

[15]  H. Hartung,et al.  Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis , 2010, Clinical neuropharmacology.

[16]  V. Brinkmann.  Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. , 2007, Pharmacology & therapeutics.

[17]  T. Hla,et al.  Immunosuppressive and Anti-angiogenic Sphingosine 1-Phosphate Receptor-1 Agonists Induce Ubiquitinylation and Proteasomal Degradation of the Receptor* , 2007, Journal of Biological Chemistry.

[18]  V. Brinkmann,et al.  The Heart Rate Decrease Caused by Acute FTY720 Administration Is Mediated by the G Protein‐Gated Potassium Channel IKACh , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  G. Chrebet,et al.  Synthesis, stereochemical determination and biochemical characterization of the enantiomeric phosphate esters of the novel immunosuppressive agent FTY720. , 2004, Bioorganic & medicinal chemistry.

[20]  R. Proia,et al.  Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes , 2004, Journal of Pharmacology and Experimental Therapeutics.

[21]  J. Kovarik,et al.  Multiple‐Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects , 2004, Journal of clinical pharmacology.

[22]  R. Proia,et al.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.

[23]  Y. Okamoto,et al.  Sphingosine-1-phosphate signaling and cardiac fibrosis , 2013 .